Investment Pitches

Pitch Summary:
NerdWallet is positioned for continued growth, driven by its strategic focus on expanding its audience, integrating acquisitions, and enhancing user engagement through data-driven initiatives. The company's strong financial performance, with significant revenue growth and a robust balance sheet, supports its ability to capitalize on new opportunities and withstand potential macroeconomic challenges. Despite risks from AI-driven search results, NerdWallet's high-quality content and diversified revenue streams make it a compelling investment.

BSD Analysis:
NerdWallet's revenue growth of 29% year-over-year in Q1 2025, particularly in its insurance segment, underscores its ability to capitalize on emerging verticals. The company's strategic acquisition of Next Door Lending enhances its vertical integration, improving unit economics and expanding its mortgage business. With a forward P/S ratio below the sector median and historical averages, NerdWallet appears undervalued, presenting an attractive entry point for investors. While AI-driven search results pose a risk, NerdWallet's focus on complex financial topics and high-quality content could mitigate this threat. The company's strong balance sheet, with no long-term debt, provides flexibility for future acquisitions, further supporting its growth strategy. As the economy remains stable, NerdWallet's diversified approach and strategic initiatives position it well for sustained performance.

Pitch Summary:
Lamb Weston appears undervalued at its current trading price of $51, especially when compared to the broader market's valuation. The company is trading at approximately 16 times its 2025 earnings, which is lower than the S&P 500's average. With earnings expected to grow by 10% in 2026 and 12% in 2027, the forward P/E ratio could decrease further, making it an attractive investment. Additionally, Lamb Weston has initiated a turnaround plan to enhance efficiency and reduce costs, potentially saving up to $85 million annually by 2026. The company's potential as a takeover target, with interest from firms like Post Holdings and possibly McDonald's, adds another layer of upside potential for investors.

BSD Analysis:
Lamb Weston's strategic initiatives to improve operational efficiency and introduce new product innovations are crucial for enhancing profitability. The company's debt level of $4.27 billion is manageable given its cash flow generation and the potential cost savings from its turnaround plan. The involvement of activist investor Jana Partners, which holds a 5% stake, underscores the potential for operational improvements and a possible sale, which could unlock shareholder value. The company's dividend yield of nearly 3% is attractive, especially in a declining interest rate environment, and its share buyback program further supports shareholder returns. The defensive nature of Lamb Weston's business, centered around staple food products like French fries, provides resilience against economic downturns, making it a compelling investment in uncertain times. However, investors should remain cautious of potential risks, including weak consumer demand and challenges in executing cost-cutting measures.

Pitch Summary:
Novavax, Inc. is currently facing significant challenges despite a recent revenue surge, primarily due to one-off payments rather than sustainable growth. The company's reliance on its COVID-19 vaccine, Nuvaxovid, and its partnership with Sanofi highlights a lack of diversification in revenue streams. The reduction in R&D spending further limits future growth prospects, making the stock unattractive. The valuation appears artificially low due to these non-recurring revenue boosts, and without a strategic shift towards diversifying its pipeline and revenue sources, the stock remains a sell.

BSD Analysis:
Novavax's recent financial performance, with a Q1 2025 revenue spike to $666.7 million, is largely attributed to the termination of Advanced Purchase Agreements and not indicative of ongoing business strength. The company's heavy reliance on Sanofi for revenue generation, coupled with a significant reduction in R&D spending, suggests a lack of strategic foresight. The biotechnology sector is highly competitive, with peers like Moderna and Pfizer having diversified their pipelines significantly post-pandemic. Novavax's focus on a combination COVID-flu vaccine may not suffice to offset declining demand for COVID-only vaccines. The company's financial strategy, prioritizing debt reduction over R&D investment, may hinder its ability to capitalize on future growth opportunities. Without a clear path to diversify and strengthen its product pipeline, Novavax's long-term viability remains questionable, reinforcing the bearish outlook on the stock.

Pitch Summary:
Barry Callebaut is positioned as an attractive investment due to its low valuation and the inelastic demand for chocolate. Despite short-term volatility driven by high cocoa bean prices, the company is expected to benefit from efficiency improvements and market normalization. The stock is undervalued compared to historical P/E ratios, offering significant upside potential as the market stabilizes.

BSD Analysis:
Barry Callebaut's strategic focus on standardization and efficiency, including the rollout of new factories, positions it well to manage current market challenges. The company's efforts to deleverage and reduce working capital intensity are prudent, aiming for a net debt/EBITDA ratio below 3.5x. While cocoa prices remain high, Barry Callebaut's ability to pass costs onto consumers due to the inelastic nature of chocolate demand supports its revenue growth. The company's valuation, currently below 16x P/E, is attractive compared to its historical average of 25-30x P/E, suggesting a potential reversion to mean valuation levels. The anticipated recovery in earnings by 2026, coupled with a conservative P/E assumption of 22-23x, underpins the forecasted 100%+ return on investment by 2028. Despite short-term risks, the long-term outlook remains positive, making Barry Callebaut a compelling buy for patient investors.

Pitch Summary:
Global Ship Lease is positioned to benefit from strong chartering rates and a resilient balance sheet. The company has secured long-term contracts at favorable rates, ensuring stable cash flows. Management's strategic capital allocation, including dividend growth and debt reduction, enhances shareholder value. The ongoing disruptions in global trade routes further support high charter rates, providing a favorable environment for GSL's operations.

BSD Analysis:
Global Ship Lease has demonstrated robust financial management by significantly deleveraging its balance sheet, reducing net debt to EBITDA from 8.4x in 2018 to below 1x. This financial strength allows the company to sustain and potentially increase its dividend, currently yielding 7.8%. The strategic decision to pause buybacks in favor of dividend hikes indicates management's focus on enhancing shareholder returns through yield-driven stock price appreciation. Despite geopolitical risks, such as disruptions in the Red Sea, the tight vessel supply and high charter rates provide a strong margin of safety. GSL's valuation remains attractive, trading at a P/E of 2.8x, which is competitive compared to peers like Danaos. The company's growing book value and discounted trading relative to NAV further underscore its investment appeal.

Pitch Summary:
eBay is positioned as a buy due to its robust fundamentals and the potential for increased demand in the second-hand market driven by tariffs and inflation. As prices for new goods rise, eBay's platform, which specializes in second-hand items, becomes more attractive to cost-conscious consumers. The company's refurbished program adds value by offering warranties and support, enhancing customer trust and potentially boosting sales. Despite slow revenue growth, eBay's valuation remains appealing with a reasonable P/E ratio and strong profit margins compared to its peers.

BSD Analysis:
eBay's financial health is underscored by a solid balance sheet, with $4.794 billion in cash and short-term investments against $5.88 billion in current liabilities. The company's net income margin of 19.78% significantly outpaces the sector median of 4.4%, highlighting its operational efficiency. While revenue growth is modest at 1.52% year-over-year, the potential for increased consumer shift towards second-hand goods amid economic pressures could serve as a catalyst for future growth. eBay's valuation, with a trailing P/E ratio of 18.33, is competitive, especially when compared to peers like Walmart and Etsy. The company's ability to achieve a free cash flow growth of 9.78% and EPS growth of 7.77% appears feasible, supporting its investment case. Overall, eBay's strategic positioning in the value retail space, coupled with favorable macroeconomic trends, presents a compelling opportunity for investors.

Pitch Summary:
Southwest Airlines is positioned to benefit from strong domestic travel demand and potential revenue growth from new routes and partnerships, such as its collaboration with Icelandair. However, its profit margins lag behind peers, and a recent negative outlook from Fitch adds caution. The stock's current valuation reflects optimism about future earnings growth, but challenges remain, including competitive pressures and the impact of new fees on customer loyalty.

BSD Analysis:
Southwest Airlines' forward revenue growth of 4.7% exceeds the sector average, indicating potential for top-line expansion. However, its EBITDA margin of 6.8% and net income margin of 1.98% are below industry norms, suggesting room for operational improvement. The company is actively pursuing cost efficiencies, targeting $1 billion in savings by 2027, which could enhance profitability. Despite a favorable debt-to-equity ratio of 0.71, Fitch's negative outlook highlights economic headwinds that may hinder profitability restoration. The stock's forward P/E of 37.98 suggests high expectations for earnings growth, supported by a projected EPS increase of nearly 41%. While the stock's dividend yield is modest at 1.9%, its cash flow growth remains a concern, with trailing operating cash flow down 39%. Overall, Southwest's strategic initiatives and market position offer potential upside, but investors should weigh these against sector volatility and competitive dynamics.

Pitch Summary:
HA Sustainable Infrastructure Capital, Inc. (HASI) faces significant headwinds due to recent legislative changes that repeal key clean energy tax credits. These changes threaten to disrupt HASI's investment pipeline and challenge its ability to meet its earnings growth targets. Despite the company's reaffirmation of its EPS growth guidance through 2027, the increased tax burden and potential delays in project execution present substantial risks. The company's reliance on issuing new shares and accumulating debt further complicates its financial stability, making it a cautious hold for now.

BSD Analysis:
HASI's financial health is under pressure due to its negative free cash flow and increasing debt levels, which have grown by 116% over the past five years. The company's strategy of asset rotation has not sufficiently offset the decline in adjusted EPS, which fell by 4 cents per share compared to the previous year. The legislative rollback of the Inflation Reduction Act's tax credits, now replaced by the One Big Beautiful Bill, poses a severe threat to HASI's business model, which heavily relies on these incentives. While the company has a substantial investment pipeline of over $5.5 billion, the uncertainty surrounding future projects and the potential for increased taxation could hinder its growth prospects. Investors should be wary of the dilution risk, as HASI's shares outstanding have increased by 81% over five years, reflecting an annualized dilution rate of 16%. Given these challenges, HASI's ability to achieve its 10% EPS growth target by 2027 remains uncertain, and its current cash position limits its flexibility to navigate these headwinds effectively.

Pitch Summary:
Harrow, Inc. has demonstrated impressive growth by leveraging its strong foothold in the ophthalmic compounding pharmacy niche to transition into the branded pharmaceutical space. The company has consistently achieved a 40% CAGR in revenue over the past decade and is expected to maintain or even accelerate this growth rate. Harrow's strategic acquisitions, such as the recent purchase of Byqlovi, position it well to capture significant market share in the ophthalmic drug market. The company's innovative share-based compensation structure aligns management's incentives with shareholder value, targeting a substantial increase in share price. With a robust pipeline and strong operational leverage, Harrow is poised for continued success.

BSD Analysis:
Harrow's strategic pivot into the branded pharmaceutical market is supported by its existing relationships with approximately half of ophthalmic drug prescribers, providing a ready customer base for new product launches. The company's acquisition of Byqlovi, a drug for post-ocular surgery inflammation and pain, exemplifies its low-risk, high-reward acquisition strategy, which involves minimal upfront costs and potential for significant revenue through royalties. Harrow's financial performance is bolstered by increasing EBITDA margins, which are projected to exceed 25% in 2025, reflecting strong operational efficiency. The company's ambitious internal price targets, such as 'Project 100,' signal management's confidence in achieving substantial share price appreciation. Despite potential risks from regulatory changes and debt refinancing, Harrow's robust growth trajectory and strategic positioning in the ophthalmic drug market make it an attractive investment opportunity. The company's ability to efficiently launch new drugs and capitalize on its extensive distribution network further enhances its competitive advantage in the pharmaceutical industry.

Pitch Summary:
EPR Properties has shown resilience post-pandemic, but its heavy reliance on the movie theater industry poses significant risks. The stock trades at a slight discount to more diversified peers, which does not adequately reflect the potential headwinds from its concentrated tenant base. The secular decline in the movie theater sector could impact EPR's cash flow and valuation multiples, warranting a cautious stance.

BSD Analysis:
EPR Properties' current valuation offers a dividend yield of approximately 5.9%, only marginally higher than its more diversified peers like Realty Income and W. P. Carey. This slim discount is concerning given EPR's 38% EBITDARe exposure to movie theaters, a sector facing long-term secular decline. The company's FFO margin of 52% is notably lower than Realty Income's 68%, suggesting less operational efficiency and greater vulnerability to declining revenues. While EPR has managed to achieve revenue and FFO growth, much of this is attributed to favorable comparables from 2024. The company's strategy of high dispositions relative to acquisitions indicates a focus on portfolio quality, but the ongoing risks from theater tenants could lead to a re-rating. Investors might find better opportunities in more diversified REITs unless EPR's yield increases to reflect a higher risk premium.

Pitch Summary:
Spotify has shown significant operational improvements, transitioning from a cash-burning entity to one with positive free cash flow and improved margins. However, its current valuation appears stretched, with multiples far exceeding historical norms. The stock's high price reflects a level of execution that leaves little room for error, suggesting a potential correction if expectations are not met.

BSD Analysis:
Spotify's recent financial performance has been bolstered by strategic cost management and innovative monetization strategies, such as reducing payouts to creators and leveraging AI to enhance content offerings. Despite these improvements, the stock's valuation at 117x trailing earnings and 71x forward earnings is concerning, especially given the company's 16% YoY sales growth. Analysts project robust EPS growth, but achieving these targets may be challenging without further margin expansion. Operating costs, which have been well-controlled, could rise as the company scales, potentially impacting profitability. The current P/S ratio is at a five-year high, suggesting the stock is overheated. Investors should be cautious, as the high valuation may not be sustainable in the face of potential operational challenges and market volatility.

Pitch Summary:
Blackstone Mortgage Trust, Inc. (BXMT) is positioned as a hold for income-focused investors due to its strong management team and historical reliability in income distribution. Despite a recent dividend cut and challenges in profitability, the company is making strategic moves to stabilize its portfolio, such as entering a joint venture to acquire net lease properties. This strategy mirrors successful models like Starwood Properties, potentially providing a new income stream and reducing risk exposure.

BSD Analysis:
BXMT's strategic pivot towards acquiring net lease properties is a calculated move to diversify its income streams and mitigate risks associated with its traditional mortgage portfolio. The company's $18 billion loan portfolio, with a conservative 63% loan-to-value ratio, provides a buffer against potential defaults. However, the recent dividend cut and the need to reserve funds for credit losses indicate ongoing profitability challenges. The company's connection to Blackstone, the world's largest alternative asset manager, offers a competitive advantage through access to extensive market data and resources. While BXMT's current dividend yield of 9.34% is attractive, the market's concerns about office vacancy and interest rate risks remain pertinent. The upcoming Q2 2025 results will be crucial in assessing the effectiveness of BXMT's strategic initiatives and its ability to return to consistent profitability.

Pitch Summary:
Nokia has successfully transformed itself from a mobile phone manufacturer into a key player in the telecommunications infrastructure sector. The company is well-positioned to benefit from the global rollout of 5G networks and the expansion of private wireless networks. Its strong patent portfolio provides a competitive edge and a steady revenue stream. With a robust balance sheet and improving free cash flow, Nokia's current valuation appears significantly undervalued, offering a compelling opportunity for long-term investors.

BSD Analysis:
Nokia's strategic pivot towards network infrastructure and cloud services has positioned it favorably in the telecommunications industry. The company's focus on 5G technology and private wireless networks aligns with global trends, providing substantial growth opportunities. Nokia's patent portfolio, particularly in 5G, generates high-margin revenue, contributing to its financial stability. The company's discounted cash flow model suggests a fair value significantly higher than its current market price, indicating potential for substantial upside. Despite risks such as geopolitical tensions and reliance on telecom capital expenditures, Nokia's strong financials and strategic initiatives mitigate these concerns. Its valuation metrics, including a low EV/Sales ratio compared to peers, further underscore its attractiveness as an investment.

Pitch Summary:
Global Ship Lease is positioned as an attractive investment due to its strong financial health, substantial contracted revenues, and a robust dividend yield. The company has a solid backlog with long-term contracts, ensuring revenue stability. Despite a recent 30% rise in stock price, the valuation remains appealing with a potential upside to a fair value of $35 per share. The company's focus on deleveraging and returning capital to shareholders through dividends further enhances its investment appeal.

BSD Analysis:
Global Ship Lease's financial strength is underscored by its $428 million in cash against $777 million in debt, alongside a fleet valued at $1.9 billion. The company’s dividend yield of 7.8% is supported by a payout ratio of less than 25% of EPS, suggesting room for further dividend increases. The strategic focus on deleveraging is likely to enhance enterprise value, while the substantial contracted revenue backlog mitigates risks associated with market volatility. However, potential risks include management's past decision to issue shares unnecessarily and the broader sector risk of a large container order book. Despite these, the company's conservative management and focus on fleet renewal are seen as positives, maintaining its attractiveness as a yield-focused investment.

Pitch Summary:
Bio-Techne: Coveted Life Sciences Asset On Sale Due to Academic Pressures

Summary Thesis:
1) Market leading life sciences reagents and instrument company. Recurring consumable revenue, strong profit margins, healthy free cash flow and a net cash position.
2) Concern around US academic funding is weighing on shares of TECH, pressuring the stock to its lowest valuation since 2017.
3) Revenue growth rate inflecting higher in FY '27 (6/30 FYE) as Company laps one-time NIH budget reset and growth assets propel consolidated revenue.
4) Coveted asset as evidenced by recent M&A transactions, which supports a significantly higher valuation than implied by current share price.

Bio-Techne ("TECH") develops, manufactures and sells life science reagents, instruments and services for the research, pharmaceutical, diagnostics and bioprocessing markets worldwide. Founded in 1976 as Research and Diagnostic Systems, the company IPO'd in 1985 when it merged with Techne Corporation. TECH has been a leader in manufacturing high-quality antibodies and proteins used in life sciences research. The Company also manufactures instruments that utilize these reagents, creating a razor/razor blade model. In 2013, the Company embarked on a strategy to accelerate revenue growth by utilizing cash flow from its Protein Sciences business to acquire higher growth products leveraged to its existing customer base. Today, 80% of the company's revenues are consummables, driving highly recurring revenue for the company. Customer concentration is minimal given TECH's broad product and customer base. Today, the Company operates in two segments: Protein Sciences and Diagnostics & Genomics.

Protein Sciences – TECH's Crown Jewel

Protein Sciences represents the original TECH business that sells reagents and instruments into research and diagnostics markets. Key customers in this segment include research institutions, biopharma, pharma and diagnostics companies. TECH's proteins and antibodies are widely used in academic research, which in addition to patent and trademark protection, provides important validation for the quality of the products. Academic citations also serve as a strong marketing tool for TECH's products and help to drive future sales. On the equipment side, TECH's growing installed base of instruments provides visibility into ongoing utilization of TECH's products.

More recently, TECH has broadened its customer base and now sells GMP grade proteins that are utilized in the production of cell and gene therapies ("C>"), both in clinical trials and FDA approved commercial products. The C> business represents a growth opportunity for the segment as clinical trial customers (85 today) ultimately convert to commercial customers (4 today). The core reagents and instruments business has historically grown at mid to high single digit rate as ongoing innovation in drug discovery and development has fueled strong demand for TECH's products. While comprising only ~11% of Protein Sciences revenue today, TECH's emerging C> business is projected to sustain its +20% growth rate over the next few years, supporting ongoing growth for this segment. Gross margins for the Protein Sciences segment are ~75% and the business generates an impressive 45% operating margin. The Protein Sciences segment accounts for ~70% of TECH's revenue and 95% of consolidated operating income. This is the crown jewel of Bio-Techne.

Diagnostics and Genomics – TECH's Venture Capital Portfolio

TECH's Diagnostics and Genomics business represents a collection of assets that have been acquired since the 2013 strategy shift. Many of these businesses are small and each one specializes in niche diagnostic and research markets. Key areas of focus include spatial biology, liquid biopsy, molecular diagnostics and diagnostic reagents. Understanding each of these businesses in detail is very difficult as the science is beyond my comprehension. Instead, I think of this segment as the venture capital portfolio of TECH. Each of these businesses represents a call option for a potentially significant business. Given the small size of each company in this segment, it is difficult to underwrite significant value from any individual asset today. Given that many of the businesses in this segment are emerging and require significant marketing and R&D, operating margins for this segment are depressed at ~7%. While not a meaningful source of earnings today, there is significant potential from this portfolio via operating leverage and a focus by management on margin improvement. I trust that TECH is appropriately sizing its bets in these markets and that the portfolio will ultimately deliver shareholder value.

Investment Opportunity – Customer Budget Concerns

TECH's stock has been hit hard by concerns around cuts to NIH/NSF funding, which will have a direct impact on the 12% of TECH's revs that are generated from US academic customers. As proposed today, the 2026 fiscal budget would cut the NIH budget by 40%. TECH's revenues should be less exposed to the full 40% cut for a myriad of reasons (less indirect cost exposure, consummables focus, priority funding areas, etc), but this figure is a good baseline to run sensitivity analysis around NIH exposure. TECH also has risks related to China revenue (8% of revs) and general uncertainty around pharma and biopharma spending. No matter how you slice it, it's hard to envision TECH generating significant revenue growth in FY '26 (6/30/26 YE). This uncertainty has weighed on not only TECH's stock, but also the broader healthcare sector and life sciences tools industry. While the chart below illustrates Healthcare's underperformance for large caps, the same dynamic is occurring in small caps.

As a result of the pressure on the healthcare sector broadly as well as specific risks to TECH's revenues, the Company's shares traded down to a multiple not seen since 2017. While the absolute multiple by itself is likely at or near a floor, it was interesting that TECH's multiple also approached that of Thermo Fisher ("TMO"). TMO has always been considered a natural acquirer given that TECH already has a commercial distribution agreement with Thermo in its Protein Sciences segment. Additionally, TECH's CEO, CFO and President of Protein Sciences all held previous roles at TMO. As can be seen below, TECH's shares have historically traded at a premium to TMO given faster revenue growth rates and an embedded take-out premium (from TMO or any other larger cap player). This provides some comfort that shares of TECH are likely at or near a trough valuation.

Financial Outlook and Valuation

It's reasonable to assume that TECH's revenue in FY '26 will probably be flat with FY'25 as pressure on US academic revenue is offset by growth in C> and other smaller growth assets. Margins can likely be maintained in '26 as margin compression in Protein Sciences is offset by improvement in Diagnostics. More importantly, FY '26 is likely to represent trough earnings for TECH. Once the Company digests the one-time reset of the NIH budget cuts, growth assets should support consolidated revenue growth in 2027. Additionally, TECH will continue to generate strong free cash flow during FY '26 and, absent M&A, will operate in a net cash position within the next year. TECH is unquestionably one of the highest quality assets in the life sciences space and it appears that we are buying this A+ asset at a trough multiple on trough earnings. Investors may need to wait 12 months for the market to recognize that earnings are inflecting in 2027, but this is exactly the type of market inefficiency that the Headwaters Capital portfolio seeks to exploit via a patient and elongated investment time horizon. Management believes the business will return to long-term double-digit revenue growth after next year and margin expansion should support mid-teens earnings growth. Given the scarcity of this asset and strong growth and margin profile, TECH will likely trade at a 20-25x EBITDA multiple once growth resumes. Using a 20x multiple on my 2027 EBITDA forecast yields a price target of $64, or +27% upside from the $50 average purchase price. 25x yields a $78 price target or +57% upside.

M&A Value

Readers may notice that TECH's Protein Sciences segment is similar to a previous Headwaters Capital investment, Abcam, which was ultimately acquired by Danaher. I was initially attracted to Abcam through research I had done on TECH years ago. I always admired TECH's protein sciences business, but I could never get comfortable with Bio-Techne's valuation which seemed to assign excessive value for its portfolio of smaller growth businesses. At today's multiple, investors don't need to ascribe any value to these growth businesses as the Protein Sciences segment itself is trading at a discount to recent transactions. Using comparable transactions in the antibody and protein space, we can see that there has been substantial M&A interest in peers over the last few years. A 30x EBITDA multiple on trough 2026 earnings would yield a price target of $82, or +64% upside. I sincerely hope that TECH would not sell the Company based on 2026 earnings, but it's a useful sanity check on the true value of the Company.

BSD Analysis:
Headwaters Capital presents a compelling contrarian thesis on Bio-Techne, arguing the market has oversold a high-quality life sciences tools company due to temporary academic funding concerns. The manager highlights TECH's dominant market position in reagents and instruments with 80% recurring consumable revenue, 75% gross margins in its core Protein Sciences segment, and strong free cash flow generation. The investment opportunity centers on NIH budget cut fears creating a trough valuation (lowest since 2017) for what the manager considers an "A+ asset." Key catalysts include the emerging cell & gene therapy business growing at 20%+ rates and expected earnings inflection in FY2027 as the company laps one-time budget pressures. The manager sees significant M&A potential given recent comparable transactions at 30x+ EBITDA multiples, with natural acquirer Thermo Fisher having existing commercial relationships and management connections. With price targets of $64-82 representing 27-64% upside, the thesis relies on patient capital recognizing quality fundamentals once temporary headwinds subside.

Pitch Summary:
Sidetrade SA has taken a decisive step forward in enterprise finance with the launch of the world's first autonomous AI Cash Collection Agent. This isn't incremental innovation – it's a structural shift in how working capital is managed. The agent, Aimie, operates live and independently, orchestrating the full Order-to-Cash (O2C) cycle: initiating outbound calls, engaging with debtors, qualifying outcomes, escalating risks, and continuously learning from real-time interactions. What makes this launch particularly compelling is the scale and depth of Sidetrade's data advantage. Aimie is trained on trillions of dollars in payment experiences across millions of buyers, powered by Sidetrade's proprietary data lake – the largest real-time behavioural database in the O2C space. This enables precision decision-making and adaptive outreach strategies that go far beyond traditional rule-based automation. Thereby, Sidetrade is positioning itself as a category leader in intelligent cash flow management. Early adopters are already reporting meaningful reductions in DSO and improved consistency in execution – two metrics that directly impact liquidity and margin. Moreover, the agentic model allows enterprises to redeploy finance teams from repetitive tasks to strategic initiatives, unlocking both cost efficiencies and human capital leverage. Imagine a collections department of 40 people. With Aimie, much of the repetitive, manual work is automated – freeing teams to focus on strategic, high-impact tasks. The result? Lower costs, higher margins, and a more human finance function – ironically, powered by AI. Sidetrade's long-term investment in domain-specific AI models (dating back to 2015) and its unified enterprise platform and data lake give it a defensible moat as well as a first mover advantage. With Aimie now capable of making thousands of outbound calls daily in multiple languages, the company is well-positioned to further scale across Europe and North America.

BSD Analysis:
The manager presents Sidetrade as a transformational AI-powered fintech company that has achieved a breakthrough with its autonomous cash collection agent, Aimie. The investment thesis centers on Sidetrade's proprietary data advantage, with the largest real-time behavioral database in the Order-to-Cash space trained on trillions of dollars in payment experiences. The manager views this as a structural shift rather than incremental innovation, positioning Sidetrade as a category leader in intelligent cash flow management. Early customer adoption is already demonstrating measurable improvements in Days Sales Outstanding (DSO) and execution consistency, directly impacting client liquidity and margins. The agentic AI model creates significant operational leverage by automating repetitive tasks and allowing finance teams to focus on strategic initiatives. The manager emphasizes Sidetrade's first-mover advantage and defensible moat through its decade-long investment in domain-specific AI models since 2015. The scalability potential across Europe and North America, combined with multi-language capabilities, suggests significant growth runway ahead.

Pitch Summary:
In the last Letter to Partners, I outlined my conviction in Fortnox AB – a Swedish leader in enterprise resource planning (ERP) software with monopoly-like economics. Shortly after I initiated the position, private equity firm EQT and the company's Chairman proposed a take-private transaction. The deal has now closed at SEK 89.75 per share. I paid SEK 64.80 per share and received a dividend of SEK 0.25, resulting in a return of +38.89%. While it's gratifying to see this thesis validated so quickly, the real story lies in what the transaction signals: private markets are increasingly recognizing the long-term compounding power of mission-critical Software-as-a-Service (SaaS) businesses with embedded workflows and robust data access. Fortnox's ability to expand into adjacent financial services beyond accounting, drive progressively higher margins, and innovate relentlessly made it a natural target. I wouldn't be surprised if, within a few years, the company returns to public markets at a multiple of its current size and scope.

BSD Analysis:
The manager's thesis on Fortnox AB was validated through a successful take-private transaction by EQT, generating a 38.89% return in a short timeframe. The investment was predicated on Fortnox's monopoly-like economics in Swedish ERP software and its mission-critical SaaS platform with embedded workflows. The manager emphasizes the company's ability to expand into adjacent financial services beyond core accounting functions, suggesting strong cross-selling opportunities and revenue diversification. The take-private at a significant premium validates the manager's view that private markets recognize the compounding power of data-rich, workflow-embedded software businesses. The manager expects Fortnox to continue scaling under private ownership, potentially returning to public markets at a much larger scale. This successful exit demonstrates the manager's ability to identify undervalued software assets with defensive moats and expansion potential. The transaction also signals broader market recognition of the value creation potential in mission-critical enterprise software platforms.

Pitch Summary:
@secretlyaninja argues that KITW.L is deeply undervalued despite being a high-quality, high-ROIC food distributor with a long history of disciplined capital allocation. The company historically delivered 15–20% ROIC, and although recent results were temporarily diluted by a major acquisition, the long-term economics remain strong. Insider buying underscores management conviction, while the stock’s 15% FCF yield supports significant compounding. Private equity interest could provide a fast path to re-rating. With normalized EPS and historical multiples, the author sees 82% upside to 455p, plus dividends bringing total returns near 90%.

BSD Analysis:
Kitwave operates in a defensive distribution niche with scale-driven efficiencies and strong cash generation. Its acquisition model allows ROIC-accretive bolt-ons at low multiples, supporting long-term compounding. Competitive pressures are moderate, and switching costs in wholesale channels provide customer stickiness. The balance sheet is conservative, enabling continued M&A. Valuation is well below global peers, and the technical overhang from a forced seller is temporary. A PE takeout is plausible given the company's ROIC profile. Overall, fundamentals and catalysts align for potential multiple expansion.

Actual Post Content:
That is way too cheap for a high quality co like $KITW. It has historically generated mgmt-reported ROIC of 15%-20%. ROIC in '24 was lower cuz it made a big acquisition near y/e. Note: I could quibble with mgmt calc but directionally I think they are correct. There's also insider buying at $KITW ~250p. In March, insiders (incl CEO) bought 290K worth of stock at 258p. In July, insiders again bought 72K worth at 239p. They clearly see value at these levels. 🤑 Pod shop bros be like: what's the catalyst? For me, $KITW cheapness is its own catalyst. When I buy at 15% FCF yield, it can compound nicely as long as co is not in death spiral. But one catalyst is PE interest. High ROIC, low lev, large TAM are catnip for PE bros. PE firms can pay a bigly premium to 250p and still do very well. $KITW is cap-lite and can grow fast by buying regional co at 5x. If PE bros don't show up, $KITW could reach ~455p in 2 yrs (35p EPS x 13 P/E). $KITW has easily traded at those multiples in the past. 82% return. That 82% return in 2 yrs is only capital gains. $KITW's cap allocation policy includes dividends (~45% payout ratio). At the moment, div yield is ~5% so TR could be ~90%. Retained cap is used for acquisitions & debt repaym't, both of which are accretive. $USFD looking to buy $PFGC. They are MUCH bigger and in the US so far from perfect comps for $KITW but comparison still interesting. $KITW has = organic rev vs both, >margins, >ROIC. Both valued at 20x P/E, 12x EBITDA while $KITW 9x & 6x respectively Liontrust sold another 4% of $KITW & are now down to 6% ownership. Probably headed to 0. Recall that Liontrust's selling in '24 precipitated 1st stock selloff. They started with 17% ownership. Once gone, unwarranted selling pressure should abate

URL: https://x.com/secretlyaninja/status/1943413420876820730

Pitch Summary:
Bio-Techne: Coveted Life Sciences Asset On Sale Due to Academic Pressures Summary Thesis: 1) Market leading life sciences reagents and instrument company. Recurring consumable revenue, strong profit margins, healthy free cash flow and a net cash position. 2) Concern around US academic funding is weighing on shares of TECH, pressuring the stock to its lowest valuation since 2017. 3) Revenue growth rate inflecting higher in FY ’27 (6/30 FYE) as Company laps one-time NIH budget reset and growth assets propel consolidated revenue. 4) Coveted asset as evidenced by recent M&A transactions, which supports a significantly higher valuation than implied by current share price. Bio-Techne (“TECH”) develops, manufactures and sells life science reagents, instruments and services for the research, pharmaceutical, diagnostics and bioprocessing markets worldwide. Founded in 1976 as Research and Diagnostic Systems, the company IPO’d in 1985 when it merged with Techne Corporation. TECH has been a leader in manufacturing high-quality antibodies and proteins used in life sciences research. The Company also manufactures instruments that utilize these reagents, creating a razor/razor blade model. In 2013, the Company embarked on a strategy to accelerate revenue growth by utilizing cash flow from its Protein Sciences business to acquire growth assets. Protein Sciences – TECH’s Crown Jewel Protein Sciences represents the original TECH business that sells reagents and instruments into research and diagnostics markets. Key customers in this segment include research institutions, biopharma, pharma and diagnostics companies. TECH’s proteins and antibodies are widely used in academic research, which in addition to patent and trademark protection, provides important validation for the quality of the products. Academic citations also serve as a strong marketing tool for TECH’s products and help to drive future sales. On the equipment side, TECH’s growing installed base of instruments provides visibility into ongoing utilization of TECH’s products. More recently, TECH has broadened its customer base and now sells GMP grade proteins that are utilized in the production of cell and gene therapies (“C>”), both in clinical trials and FDA approved commercial products. The C> business represents a growth opportunity for the segment as clinical trial customers (85 today) ultimately convert to commercial customers (4 today). The core reagents and instruments business has historically grown at mid to high single digit rate as ongoing innovation in drug discovery and development has fueled strong demand for TECH’s products. While comprising only ~11% of Protein Sciences revenue today, TECH’s emerging C> business is projected to sustain its +20% growth rate over the next few years, supporting ongoing growth for this segment. Gross margins for the Protein Sciences segment are ~75% and the business generates an impressive 45% operating margin. The Protein Sciences segment accounts for ~70...ed operating income. This is the crown jewel of Bio-Techne. Diagnostics and Genomics – TECH’s Venture Capital Portfolio TECH’s Diagnostics and Genomics business represents a collection of assets that have been acquired since the 2013 strategy shift. Many of these businesses are small and each one specializes in niche diagnostic and research markets. Key areas of focus include spatial biology, liquid biopsy, molecular diagnostics and diagnostic reagents. ... its bets in these markets and that the portfolio will ultimately deliver shareholder value. Investment Opportunity – Customer Budget Concerns TECH’s stock has been hit hard by concerns around cuts to NIH/NSF funding, which will have a direct impact on the 12% of TECH’s revs that are generated from US academic customers. As proposed today, the 2026 fiscal budget would cut the NIH budget by 40%. TECH’s revenues should be less exposed to the full 40% cut for a myriad of reasons (less indirect cost exposure, consummables focus, priority funding areas, etc), but this figure is a good baseline to run sensitivity analysis around NIH exposure. TECH also has risks related to China revenue (8% of revs) and general uncertainty around pharma and biopharma spending. N...FY ’26 (6/30/26 YE). This uncertainty has weighed on not only TECH’s stock, but also the broader healthcare sector and life sciences tools industry. While the chart below illustrates Healthcare’s underperformance for large caps, the same dynamic is occurring in small caps. As a result of the pressure on the healthcare sector broadly as well as specific risks to TECH’s revenues, the Company’s shares traded down to a multiple not seen since 2017. While the absolute multiple by itself is likely at or near a floor, it was interesting that TECH’s multiple also approached that of Thermo Fisher (“TMO”). TMO has always been considered a natural acquirer given that TECH already has a commercial distribution agreement with Thermo in its Protein Sciences segment. Additionally, TECH’s CEO, CFO and President of Protein Sciences all held previous roles at TMO. As can be seen below, TECH’s shares have historically traded at a premium to TMO given faster revenue growth rates and an embedded take-out premium (from TMO or any other larger cap player). This provides some comfort that shares of TECH are likely at or near a trough valuation.

BSD Analysis:
Bio-Techne is a life-sciences supplier that sells critical reagents, tools, and diagnostics used throughout biological research and bioprocessing. Its portfolio benefits from recurring demand across academia, pharma, and biomanufacturing. The company has been expanding into higher-margin, clinically oriented diagnostics and advanced analytics. Biotech funding cycles affect sentiment, but underlying consumable demand is resilient. Acquisitions remain a core part of the strategy, and integration has been strong historically. Margins should improve as bioprocessing grows as a share of revenue. Bio-Techne remains a diversified, high-quality picks-and-shovels name.

Pitch Summary:
IOBT is developing a peptide-based therapeutic cancer vaccine targeting IDO, a historically unsuccessful target in cancer treatment. The company's current trial data is based on a small, single-center study that does not convincingly demonstrate treatment activity independent of PD-1. The market values the company at under $100 million, reflecting skepticism about the vaccine's efficacy. The phase 3 trial design has been delayed due to event accrual, suggesting underperformance. The company's financial situation is precarious, with limited cash runway and dependency on future loan tranches contingent on trial success.

BSD Analysis:
The company's approach of using a therapeutic cancer vaccine for a target that has previously failed in phase 3 studies poses significant risks. The trial's design and data do not provide clear evidence of the vaccine's efficacy, particularly given the small sample size and lack of a futility analysis. The company's financial health is concerning, with a limited cash runway and reliance on additional funding that may not materialize if the trial fails. The lack of options and low trading volume further complicate investment strategies. Overall, the high-risk nature of the stock and the potential for it to trade near zero make it a speculative investment.